Woodline Partners LP Immuno Gen, Inc. Transaction History

Woodline Partners LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $25.3 Million - $60.9 Million	-2,033,161 Reduced 83.56%	400,000 $11.9 Million
Q3 2023 Nov 14, 2023	SELL	$14.09 - $19.87 $1.61 Million - $2.27 Million	-114,478 Reduced 4.49%	2,433,161 $38.6 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $9.55 Million - $51.1 Million	2,547,639 New	2,547,639 $48.1 Million
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $22.9 Million - $31.7 Million	5,027,027 New	5,027,027 $24.9 Million
Q1 2022 May 16, 2022	SELL	$4.26 - $7.48 $16.4 Million - $28.9 Million	-3,861,498 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $18.3 Million - $29 Million	3,861,498 New	3,861,498 $28.7 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.